A216400 Stock Overview
Provides bioanalytical and central lab services in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Invites Biocore Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,800.00 |
| 52 Week High | ₩10,000.00 |
| 52 Week Low | ₩5,000.00 |
| Beta | 0 |
| 1 Month Change | -17.14% |
| 3 Month Change | -3.17% |
| 1 Year Change | -36.82% |
| 3 Year Change | -44.23% |
| 5 Year Change | 56.76% |
| Change since IPO | -41.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| A216400 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | -2.4% | 1.5% | -1.5% |
| 1Y | -36.8% | 22.9% | -10.9% |
Return vs Industry: A216400 underperformed the KR Life Sciences industry which returned 22.9% over the past year.
Return vs Market: A216400 underperformed the KR Market which returned -10.9% over the past year.
Price Volatility
| A216400 volatility | |
|---|---|
| A216400 Average Weekly Movement | 10.2% |
| Life Sciences Industry Average Movement | 10.2% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A216400's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A216400's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Hyung-Sik Choi | www.bio-core.com |
Invites Biocore Co., Ltd. provides bioanalytical and central lab services in South Korea and internationally. It offers bioanalytical testing service during biological equivalence tests, clinical trials, toxicokinetics, nonclinical trials, vivo dynamic analysis, comparative dissolution test, and biomarker analysis; provides project strategic planning, medical translation, clinical research, quality assurance, monitoring, and data management for clinical services; and offers services, such as pharmaceutical quality control testing, emergency testing for food and drug safety, impurity testing, testing for licensed pharmaceutical products, and pharmaceutical stability testing. The company also provides disease susceptibility and anticancer drug susceptibility test; personalized genetic testing services, chromosomal microarray analysis, newborn screening, diagnostic exome sequencing, and non-invasive prenatal testing; and sequencing, microarray analysis, Real-Time PCR analysis services.
Invites Biocore Co., Ltd. Fundamentals Summary
| A216400 fundamental statistics | |
|---|---|
| Market cap | ₩44.73b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A216400 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A216400 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A216400 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 01:00 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Invites Biocore Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jang Kwan Kim | iM Securities |